PMID- 29064082
OWN - NLM
STAT- MEDLINE
DCOM- 20181009
LR  - 20221207
IS  - 1720-8386 (Electronic)
IS  - 0391-4097 (Linking)
VI  - 41
IP  - 5
DP  - 2018 May
TI  - Abnormal 1-hour post-load glycemia during pregnancy impairs post-partum metabolic 
      status: a single-center experience.
PG  - 567-573
LID - 10.1007/s40618-017-0774-z [doi]
AB  - PURPOSE: Recent evidence indicates that people with normal glucose tolerance 
      (NGT) but 1-h post-load plasma glucose (1-h OGTT) >/= 155 mg/dl have an increased 
      risk for developing Type 2 diabetes mellitus (T2DM), determining a new risk 
      category with deeper metabolic impairment. The aim of this study was to identify, 
      among women with gestational diabetes (GDM), which alterations at OGTT during 
      pregnancy are more frequently associated with 1-h OGTT >/= 155 mg/dl at post-partum 
      examination. METHODS: Among 297 women affected by GDM, we retrospectively 
      evaluated 244 resulted NGT after delivery. Based on post-partum glucose levels at 
      1-h OGTT, these people were divided into 188 cases (77.0%) with 1-h 
      OGTT < 155 mg/dl (L-NGT) and 56 (23.0%) with 1-h OGTT >/= 155 mg/dl (H-NGT). 
      RESULTS: Abnormal glucose levels at 1-h OGTT during pregnancy (>/= 180 mg/dl) were 
      more frequent in H-NGT than in L-NGT (39.3 vs. 24.6%, odds ratio 3.7 [95% CI 
      1.4-9.6]; p = 0.016). Moreover, H-NGT showed more frequently the simultaneous 
      alteration of all three OGTT plasma glucose values during pregnancy (10.7 vs. 
      2.1%, odds ratio 4.5 [95% CI 1.5-20.3]; p = 0.038) and less frequently the 
      alteration of fasting plasma glucose alone (14.3 vs. 30.8%, odds ratio 0.4 [95% 
      CI 0.1-0.7]; p = 0.028). CONCLUSIONS: Abnormal 1-h OGTT during pregnancy predicts 
      an increased risk for post-partum 1-h OGTT >/= 155 mg/dl in women with previous 
      GDM. Even if NGT after delivery, these women may require a closer long-term 
      post-partum follow-up, being at higher risk to develop future glucose 
      intolerance.
FAU - Tumminia, A
AU  - Tumminia A
AD  - Endocrinology Section, Department of Clinical and Experimental Medicine, 
      Garibaldi-Nesima Hospital, University of Catania, via Palermo 636, 95122, 
      Catania, Italy.
FAU - Milluzzo, A
AU  - Milluzzo A
AD  - Endocrinology Section, Department of Clinical and Experimental Medicine, 
      Garibaldi-Nesima Hospital, University of Catania, via Palermo 636, 95122, 
      Catania, Italy.
FAU - Cinti, F
AU  - Cinti F
AD  - Endocrinology Section, Department of Clinical and Experimental Medicine, 
      Garibaldi-Nesima Hospital, University of Catania, via Palermo 636, 95122, 
      Catania, Italy.
FAU - Parisi, M
AU  - Parisi M
AD  - Endocrinology Section, Department of Clinical and Experimental Medicine, 
      Garibaldi-Nesima Hospital, University of Catania, via Palermo 636, 95122, 
      Catania, Italy.
FAU - Tata, F
AU  - Tata F
AD  - Endocrinology Section, Department of Clinical and Experimental Medicine, 
      Garibaldi-Nesima Hospital, University of Catania, via Palermo 636, 95122, 
      Catania, Italy.
FAU - Frasca, F
AU  - Frasca F
AD  - Endocrinology Section, Department of Clinical and Experimental Medicine, 
      Garibaldi-Nesima Hospital, University of Catania, via Palermo 636, 95122, 
      Catania, Italy.
FAU - Frittitta, L
AU  - Frittitta L
AD  - Endocrinology Section, Department of Clinical and Experimental Medicine, 
      Garibaldi-Nesima Hospital, University of Catania, via Palermo 636, 95122, 
      Catania, Italy.
FAU - Vigneri, R
AU  - Vigneri R
AD  - Endocrinology Section, Department of Clinical and Experimental Medicine, 
      Garibaldi-Nesima Hospital, University of Catania, via Palermo 636, 95122, 
      Catania, Italy.
AD  - Institute of Bioimages and Biostructures, CNR, via Gaifami 18, 95126, Catania, 
      Italy.
FAU - Sciacca, L
AU  - Sciacca L
AD  - Endocrinology Section, Department of Clinical and Experimental Medicine, 
      Garibaldi-Nesima Hospital, University of Catania, via Palermo 636, 95122, 
      Catania, Italy. lsciacca@unict.it.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20171024
PL  - Italy
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
MH  - Adult
MH  - Biomarkers/analysis
MH  - Blood Glucose/analysis
MH  - Diabetes Mellitus, Type 2/*etiology
MH  - Diabetes, Gestational/*physiopathology
MH  - Female
MH  - Follow-Up Studies
MH  - Glucose Intolerance/*complications
MH  - Glucose Tolerance Test
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hyperglycemia/*complications
MH  - Metabolic Diseases/*etiology
MH  - *Postpartum Period
MH  - Pregnancy
MH  - Prognosis
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Gestational diabetes
OT  - Oral glucose tolerance test
OT  - Pregnancy
OT  - Type 2 diabetes mellitus
EDAT- 2017/10/25 06:00
MHDA- 2018/10/10 06:00
CRDT- 2017/10/25 06:00
PHST- 2017/05/07 00:00 [received]
PHST- 2017/10/13 00:00 [accepted]
PHST- 2017/10/25 06:00 [pubmed]
PHST- 2018/10/10 06:00 [medline]
PHST- 2017/10/25 06:00 [entrez]
AID - 10.1007/s40618-017-0774-z [pii]
AID - 10.1007/s40618-017-0774-z [doi]
PST - ppublish
SO  - J Endocrinol Invest. 2018 May;41(5):567-573. doi: 10.1007/s40618-017-0774-z. Epub 
      2017 Oct 24.